NERV
Minerva Neurosciences, Inc
stockNASDAQ
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.40 | 2026-09-28 | -3.53% | 2.119 |
| 1M | 4.43 | 2026-09-04 | -25.96% | 1.982 |
| 3M | 4.92 | 2026-07-06 | -33.33% | 1.308 |
| 6M | 5.23 | 2026-04-06 | -37.28% | 1.790 |
| 1Y | 2.14 | 2025-10-06 | +53.31% | 1.699 |
| 2Y | 2.62 | 2024-10-04 | +25.06% | — |
| 5Y | 11.60 | 2021-10-05 | -71.72% | 0.209 |
Minerva Neurosciences, Inc (NASDAQ:NERV) stock price today is $3.28, and today's volume is 57,022. NERV is up 1.548% today. The 30 day average volume is 150,853. NERV market cap is $156.61M with 47.75M shares outstanding.